ES
MCID: EWN003
MIFTS: 66

Ewing Sarcoma (ES) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Bone diseases, Cancer diseases

Aliases & Classifications for Ewing Sarcoma

Aliases & Descriptions for Ewing Sarcoma:

Name: Ewing Sarcoma 54 12 50 25 56 66 13 14
Neuroepithelioma 54 50 56 52 69
Ewing's Tumor 12 50 25 66
Ewings Sarcoma 12 52 69
Localized Peripheral Primitive Neuroectodermal Tumor 12 69
Ewings Sarcoma-Primitive Neuroectodermal Tumor 12 69
Peripheral Primitive Neuroectodermal Tumor 12 56
Peripheral Neuroepithelioma 66 52
Sarcoma, Ewing's 50 29
Ewing's Sarcoma 50 25
Askin Tumor 66 42
Ewing Tumor 50 25
Localized Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Extraosseous Ewings Sarcoma-Primitive Neuroepithelial Tumor 69
Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Neuroectodermal Tumors, Primitive, Peripheral 42
Neuroectodermal Tumor, Primitive 69
Pnet of Thoracopulmonary Region 12
Primitive Neuroectodermal Tumor 66
Ewing's Family Localized Tumor 12
Ewing Sarcoma Family of Tumors 66
Neuroepithelioma, Peripheral 69
Localized Ewing's Sarcoma 12
Tumor of the Ewing Family 25
Extraosseous Ewing Tumor 66
Localized Ewing Sarcoma 12
Localized Ewing's Tumor 12
Ewing Family of Tumors 25
Pnet of the Chest Wall 66
Peripheral Pnet 56
Sarcoma, Ewing 42
Askin's Tumor 69
Ppnet 56
Pnet 66
Esft 66
Pne 66
Es 66

Characteristics:

Orphanet epidemiological data:

56
ewing sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;
neuroepithelioma
Inheritance: Not applicable; Age of onset: Childhood;

HPO:

32
ewing sarcoma:
Inheritance somatic mutation


Classifications:



Summaries for Ewing Sarcoma

NIH Rare Diseases : 50 ewing sarcoma is a malignant (cancerous) bone tumor that affects children. it can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. the tumor may arise anywhere in the body, usually in the long bones of the arms and legs, the pelvis, or the chest. it may also develop in the skull or the flat bones of the trunk. there are few symptoms. the most common is pain and occasionally swelling at the site of the tumor. fever may also be present. the tumor often spreads (metastasis) to the lungs and other bones. the cause of ewing sarcoma is unknown. most cases are thought to occur randomly and many involved a reciprocal translocation between chromosomes 11 and 22. treatment depends upon a number of factors, but may include chemotherapy, radiation and/or surgical interventions. last updated: 2/13/2016

MalaCards based summary : Ewing Sarcoma, also known as neuroepithelioma, is related to neurofibromatosis and extraskeletal ewing sarcoma, and has symptoms including ewing's sarcoma and fever. An important gene associated with Ewing Sarcoma is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Chromatin Regulation / Acetylation and Transcriptional misregulation in cancer. The drugs Afinitor and Erbitux have been mentioned in the context of this disorder. Affiliated tissues include bone, endothelial and lung, and related phenotypes are embryo and muscle

UniProtKB/Swiss-Prot : 66 Ewing sarcoma: A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

Genetics Home Reference : 25 Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.

OMIM : 54 The Ewing sarcoma family of tumors (primitive neuroectodermal tumors; PNET) comprise morphologically heterogeneous... (612219) more...

Disease Ontology : 12 A bone cancer that has_material_basis in neural crest cells derives from undeveloped, undifferentiated neuroectoderm.

Wikipedia : 71 Ewing\'s sarcoma or Ewing sarcoma (/ˈjuːɪŋ/) is a malignant small, round, blue cell tumor. It is a... more...

Related Diseases for Ewing Sarcoma

Diseases related to Ewing Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
id Related Disease Score Top Affiliating Genes
1 neurofibromatosis 29.9 KIT NCAM1 PTPRC
2 extraskeletal ewing sarcoma 12.2
3 extraosseous ewings sarcoma-primitive neuroepithelial tumor 12.0
4 soft tissue peripheral neuroepithelioma 11.9
5 bone peripheral neuroepithelioma 11.8
6 dissociative seizures 11.6
7 pineoblastoma 11.4
8 bone ewing's sarcoma 11.2
9 extraosseous ewing's sarcoma 11.1
10 ewing's family of tumors 11.0
11 supratentorial primitive neuroectodermal tumor 11.0
12 sarcoma 10.9
13 askin's tumor 10.9
14 diabetic mastopathy 10.9
15 spiradenoma 10.8
16 diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 10.8
17 pudendal neuralgia 10.8
18 vitreous syneresis 10.4 CD99 EWSR1
19 ampulla of vater mucinous adenocarcinoma 10.4 ENO2 EWSR1 PTPRC
20 extranodal nasal nk/t cell lymphoma 10.4 EWSR1 FLI1 KIT
21 tibial aplasia ectrodactyly hydrocephalus 10.4 CD99 KIT
22 gliofibroma 10.4 ENO2 EWSR1 WT1
23 fallopian tube leiomyoma 10.4 KIT POU5F1 PTPRC
24 postauricular lymphadenitis 10.4 ENO2 EWSR1 FUS
25 sm-ahnmd 10.4 CD99 ENO2
26 cerebral arterial disease 10.4 ENO2 KIT PTPRC
27 atopic dermatitis 10.4 CD99 ENO2 KIT POU5F1
28 ovarian large-cell neuroendocrine carcinoma 10.4 EWSR1 FUS TAF15
29 choriocarcinoma 10.4 KIT WT1
30 liposarcoma 10.4 EWSR1 WT1
31 malignant pleural solitary fibrous tumor 10.4 ENO2 EWSR1 KIT POU5F1
32 uterine corpus sarcoma 10.4 ENO2 NCAM1
33 uterine corpus myxoid leiomyosarcoma 10.4 ENO2 NCAM1 PTPRC
34 small intestinal sarcoma 10.4 ENO2 KIT WT1
35 glomus tumor 10.3 ENO2 KIT NCAM1
36 lung benign neoplasm 10.3 IGF1R PTPRC WT1
37 kidney sarcoma 10.3 CD99 ENO2 ETV4 EWSR1 MYOG
38 hormone producing pituitary cancer 10.3 KIT MYOG WT1
39 pneumonia 10.3 ENO2 KIT WT1
40 fragile x-associated tremor/ataxia syndrome 10.3 ENO2 KIT NCAM1
41 spindle cell rhabdomyosarcoma 10.3 ENO2 MYOG WT1
42 thymus lipoma 10.3 NCAM1 WT1
43 microsporidiosis 10.3 ENO2 KIT NCAM1
44 plexopathy 10.3 CD99 ENO2 EWSR1 PTPRC WT1
45 peripheral osteosarcoma 10.3 CD99 ENO2 EWSR1 PTPRC WT1
46 palmoplantar keratosis 10.3 EWSR1 FUS MYOG
47 cranial nerve disease 10.3 ENO2 KIT NCAM1
48 freemartinism 10.3 KIT PTPRC
49 adenosarcoma 10.3 ENO2 KIT MYOG WT1
50 rectum leiomyoma 10.3 ENO2 KIT NCAM1 PTPRC

Graphical network of the top 20 diseases related to Ewing Sarcoma:



Diseases related to Ewing Sarcoma

Symptoms & Phenotypes for Ewing Sarcoma

Clinical features from OMIM:

612219

Human phenotypes related to Ewing Sarcoma:

32
id Description HPO Frequency HPO Source Accession
1 ewing's sarcoma 32 HP:0012254

UMLS symptoms related to Ewing Sarcoma:


fever

MGI Mouse Phenotypes related to Ewing Sarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.91 ERG ETV4 FLI1 FLII IGF1R KIT
2 muscle MP:0005369 9.7 ETV1 ETV4 FLI1 IGF1R KIT MYOG
3 neoplasm MP:0002006 9.5 ERG ETV4 FLI1 IGF1R KIT PTPRC
4 respiratory system MP:0005388 9.23 MYOG PTPRC WT1 ENO2 ERG EYA3

Drugs & Therapeutics for Ewing Sarcoma

FDA approved drugs:

(show all 6)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
2
Erbitux 17 46 CETUXIMAB Imclone, Bristol-Myers Squibb Approved February 2004
3
Evista 17 46 RALOXIFENE HYDROCHLORIDE Eli Lilly Approved September 2007
4
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals Approved November 2009
5
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
6
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008

Drugs for Ewing Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 903)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
4
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
10
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
12
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
13
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99011-02-6 57469
16
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
17
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
18
Mesna Approved Phase 4,Phase 3,Phase 1,Phase 2 3375-50-6 598
19
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 52-24-4 5453
21
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
22
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
23
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
24
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
25
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
26
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
27
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
28
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
29
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
30
Etanercept Approved, Investigational Phase 4,Phase 2 185243-69-0
31
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
32
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1 53608-75-6
33
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
34 Piracetam Approved Phase 4,Phase 2 7491-74-9
35
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
36
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
37
Gefitinib Approved, Investigational Phase 4,Phase 2,Phase 1 184475-35-2 123631
38
Olaparib Approved Phase 4,Phase 2,Phase 1 763113-22-0 23725625
39
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
40
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 149647-78-9 5311
41
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
42
Diazoxide Approved Phase 4,Phase 3,Phase 2 364-98-7 3019
43
Doxazosin Approved Phase 4 74191-85-8 3157
44
Phenoxybenzamine Approved Phase 4 59-96-1 4768
45
Nicotine Approved Phase 4 54-11-5 942 89594
46
Ceritinib Approved Phase 4,Phase 2,Phase 1,Early Phase 1 1032900-25-6
47
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
48
Palbociclib Approved Phase 4,Phase 1,Phase 2 571190-30-2 11431660 5005498 5330286
49
Zinc Approved Phase 4,Phase 1 7440-66-6 32051 23994
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 4524)
id Name Status NCT ID Phase
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
2 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
4 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
5 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
6 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
7 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
8 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
9 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4
10 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4
11 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
12 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
13 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
14 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
15 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
16 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
17 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
18 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
19 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
20 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
21 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4
22 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Recruiting NCT02626065 Phase 4
23 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4
24 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4
25 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
26 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
27 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4
28 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
29 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
30 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
31 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
32 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
33 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
34 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
35 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4
36 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4
37 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Active, not recruiting NCT01515189 Phase 4
38 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
39 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
40 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4
41 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4
42 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4
43 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4
44 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4
45 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
46 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
47 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3
48 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
49 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
50 Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors Unknown status NCT00278239 Phase 3

Search NIH Clinical Center for Ewing Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: sarcoma, ewing

Genetic Tests for Ewing Sarcoma

Genetic tests related to Ewing Sarcoma:

id Genetic test Affiliating Genes
1 Ewing's Sarcoma 29

Anatomical Context for Ewing Sarcoma

MalaCards organs/tissues related to Ewing Sarcoma:

39
Bone, Endothelial, Lung, Breast, Kidney, B Cells, T Cells

Publications for Ewing Sarcoma

Articles related to Ewing Sarcoma:

(show top 50) (show all 415)
id Title Authors Year
1
Ewing sarcoma of the sternal manubrium: first report of a case in Australasia and review of the literature. ( 28419662 )
2017
2
Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. ( 28417551 )
2017
3
Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. ( 28439237 )
2017
4
CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma. ( 28404587 )
2017
5
DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. ( 27894957 )
2017
6
Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial. ( 28436593 )
2017
7
Extra-skeletal Ewing sarcoma of the lumbosacral region in an adult pregnant patient: a case report. ( 28435928 )
2017
8
Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. ( 28429277 )
2017
9
Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. ( 28477025 )
2017
10
Bone adaptation of a biologically reconstructed femur after Ewing sarcoma: Long-term morphological and densitometric evolution. ( 28447127 )
2017
11
Inadvertently boarding a pirate ship: disease progression in a paediatric patient with relapsed metastatic Ewing sarcoma receiving treatment at a centre for alternative therapy in Mexico. ( 28062429 )
2017
12
Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. ( 27923328 )
2017
13
Primary Bone Anaplastic Large Cell Lymphoma Masquerading as Ewing Sarcoma: Diagnosis by Anchored Multiplex PCR. ( 28452858 )
2017
14
Primary Ewing sarcoma of the kidney: a case report and treatment review. ( 28509141 )
2017
15
Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. ( 28355116 )
2017
16
Ewing Sarcoma and Atypical Teratoid Rhabdoid Tumor. ( 28382842 )
2017
17
Outcome of resectable pediatric Ewing sarcoma of the ribs. ( 28462848 )
2017
18
Rare presentation of Ewing sarcoma metastasis to the sella and suprasellar cistern. ( 27816880 )
2017
19
Primary Ewing Sarcoma of Sphenoid Bone with Intracranial Extension: A Common Tumour at an Uncommon Location. ( 28384876 )
2017
20
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma. ( 27918348 )
2017
21
Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. ( 28507811 )
2017
22
High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. ( 27760381 )
2017
23
A Comparison of Pediatric vs. Adult Patients with the Ewing Sarcoma Family of Tumors. ( 28534008 )
2017
24
Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. ( 28062706 )
2017
25
Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses. ( 28454538 )
2017
26
Pulmonary Nodule Size <5 mm Still Warrants Investigation in Patients With Osteosarcoma and Ewing Sarcoma. ( 28060128 )
2017
27
Entering the Double Digits-Ewing Sarcoma In Adult Maxilla. ( 28472564 )
2017
28
Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. ( 28060130 )
2017
29
CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. ( 27835596 )
2016
30
Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. ( 27486822 )
2016
31
Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin. ( 27888797 )
2016
32
Severe gonadotoxic insult manifests early in young girls treated for Ewing sarcoma. ( 27537574 )
2016
33
Primary extraskeletal Ewing sarcoma of the stomach: a rare disease in an uncommon location. ( 27179157 )
2016
34
CIC-rearranged Sarcomas: A Study of 20 Cases and Comparisons With Ewing Sarcomas. ( 26685084 )
2016
35
Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. ( 27216741 )
2016
36
Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: A Rare and Lethal Entity. ( 26927724 )
2016
37
Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH. ( 26690869 )
2016
38
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. ( 26623725 )
2016
39
Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth. ( 28025760 )
2016
40
A case of small bowel metastasis from spinal Ewing sarcoma causing intussusception in an adult female. ( 27083867 )
2016
41
Reconstruction of the elbow and forearm for Ewing sarcoma of ulna: A new biological technique. ( 27186061 )
2016
42
Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma. ( 26847175 )
2016
43
Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing. ( 27077911 )
2016
44
Like or Dislike? Impact of Facebook on Ewing Sarcoma Treatment. ( 28410188 )
2016
45
Loss of Ewing sarcoma EWS allele promotes tumorigenesis by inducing chromosomal instability in zebrafish. ( 27557633 )
2016
46
PRAS40 deregulates apoptosis in Ewing sarcoma family tumors by enhancing the insulin receptor/Akt and mTOR signaling pathways. ( 27186418 )
2016
47
Rare case of small size Extraskeletal Ewing Sarcoma arising from the median nerve with paresthesia. ( 27523258 )
2016
48
Efficacy of ATR inhibitors as single agents in Ewing sarcoma. ( 27577084 )
2016
49
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. ( 27576731 )
2016
50
Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine. ( 27856382 )
2016

Variations for Ewing Sarcoma

Cosmic variations for Ewing Sarcoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 33

Copy number variations for Ewing Sarcoma from CNVD:

7 (show top 50) (show all 157)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13324 1 1 124300000 Deletion Ewing''s sarcoma
2 13741 1 1 27800000 Deletion Ewing''s sarcoma
3 16432 1 124300000 247249719 Gain Ewing''s sarcoma
4 16433 1 124300000 247249719 Gain Ewing''s sarcoma
5 16640 1 1286916 1536363 Loss Ewing''s sarcoma
6 17338 1 142400000 247249719 Gain Ewing''s sarcoma
7 17361 1 142565191 158296814 Gain AG1 Ewing''s sarcoma
8 20077 1 15300000 154800000 Gain Ewing''s sarcoma
9 20877 1 154978607 154979115 Gain HDGF Ewing''s sarcoma
10 21389 1 158408551 189951958 Gain FREB Ewing''s sarcoma
11 27410 1 208096981 208097464 Gain C1orf107 Ewing''s sarcoma
12 27922 1 215848737 215849264 Copy number GPATCH2 Ewing''s sarcoma
13 28256 1 220611046 220683633 Loss FBXO28 Ewing''s sarcoma
14 28623 1 224110806 224111244 Gain TMEM63A Ewing''s sarcoma
15 29204 1 228895774 228896323 Gain COG2 Ewing''s sarcoma
16 29247 1 229426179 229426672 Copy number C1orf131 Ewing''s sarcoma
17 29294 1 2300000 27800000 Deletion Ewing''s sarcoma
18 29735 1 234815741 234816376 Gain HEATR1 Ewing''s sarcoma
19 31804 1 3118000 5001000 Deletion Ewing''s sarcoma
20 31805 1 3118000 5001000 Deletion Ewing''s sarcoma
21 34220 1 53642491 53911866 Loss DMRTB1 Ewing''s sarcoma
22 35775 1 67181498 104009233 Loss SLC35D1 Ewing''s sarcoma
23 37996 1 9778925 10706826 Deletion APITD1 Ewing''s sarcoma
24 37997 1 9778925 10706826 Deletion CLSTN1 Ewing''s sarcoma
25 37998 1 9778925 10706826 Deletion CORT Ewing''s sarcoma
26 37999 1 9778925 10706826 Deletion CTNNBIP1 Ewing''s sarcoma
27 38000 1 9778925 10706826 Deletion DFFA Ewing''s sarcoma
28 38001 1 9778925 10706826 Deletion LZIC Ewing''s sarcoma
29 38002 1 9778925 10706826 Deletion NMNAT1 Ewing''s sarcoma
30 38003 1 9778925 10706826 Deletion PEX14 Ewing''s sarcoma
31 38004 1 9778925 10706826 Deletion PGD Ewing''s sarcoma
32 38005 1 9778925 10706826 Deletion RBP7 Ewing''s sarcoma
33 38141 10 1 135374737 Deletion Ewing''s sarcoma
34 41153 10 138206 135293404 Gain Ewing''s sarcoma
35 48491 11 1 52900000 Gain Ewing''s sarcoma
36 55430 11 52900000 134452384 Gain Ewing''s sarcoma
37 59789 11 777331 821974 Loss BM88 Ewing''s sarcoma
38 60445 11 86456481 127953177 Loss Ewing''s sarcoma
39 61420 12 1 132349534 Gain Ewing''s sarcoma
40 61533 12 1 35400000 Gain Ewing''s sarcoma
41 62737 12 111075038 111075556 Gain TRAFD1 Ewing''s sarcoma
42 63302 12 116955326 116955682 Copy number WSB2 Ewing''s sarcoma
43 64487 12 12873623 12874134 Gain DDX47 Ewing''s sarcoma
44 65323 12 1570852 1571348 Copy number FBXL14 Ewing''s sarcoma
45 66228 12 2670999 2671234 Deletion CACNA1C Ewing''s sarcoma
46 67041 12 35400000 132349534 Gain Ewing''s sarcoma
47 67472 12 41121456 41121979 Gain PPHLN1 Ewing''s sarcoma
48 68463 12 49967 52715434 Gain IQSEC3 Ewing''s sarcoma
49 68787 12 51501640 51502010 Copy number KRT79 Ewing''s sarcoma
50 69068 12 52981304 57130106 Gain Ewing''s sarcoma

Expression for Ewing Sarcoma

Search GEO for disease gene expression data for Ewing Sarcoma.

Pathways for Ewing Sarcoma

GO Terms for Ewing Sarcoma

Biological processes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription, DNA-templated GO:0006351 9.9 ATF1 ERG ETV1 ETV4 EWSR1 EYA3
2 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.86 ATF1 ERG ETV1 ETV4 FLI1 MYOG
3 positive regulation of transcription, DNA-templated GO:0045893 9.8 ETV1 ETV4 MYOG TAF15 WT1
4 transcription from RNA polymerase II promoter GO:0006366 9.5 ATF1 ERG ETV1 ETV4 FLI1 POU5F1
5 regulation of transcription, DNA-templated GO:0006355 9.4 ATF1 ERG ETV1 ETV4 EWSR1 EYA3
6 mRNA transcription from RNA polymerase II promoter GO:0042789 9.37 MYOG POU5F1
7 megakaryocyte development GO:0035855 9.32 FLI1 KIT

Molecular functions related to Ewing Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.77 ERG ETV1 ETV4 FLI1 MYOG
2 transcription factor activity, sequence-specific DNA binding GO:0003700 9.76 ATF1 ERG ETV1 ETV4 FLI1 MYOG
3 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.71 ERG ETV4 FLI1 POU5F1
4 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.43 ERG ETV1 ETV4 FLI1 MYOG WT1
5 sequence-specific DNA binding GO:0043565 9.23 ATF1 ERG ETV1 ETV4 FLI1 MYOG
6 protein binding GO:0005515 10.21 ATF1 CD99 ENO2 ERG ETV1 ETV4
7 DNA binding GO:0003677 10.02 ATF1 ERG ETV1 ETV4 FLI1 FUS

Sources for Ewing Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....